Investors

Webcast ImageWebcast
Coherus Biosciences Inc at Baird 2016 Healthcare Conference (Live)
09/07/16 at 9:40 a.m. ET
Coherus Biosciences Inc at Baird 2016 Healthcare Conference
Wednesday, September 7, 2016 9:40 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Coherus Biosciences at Morgan Stanley Global Healthcare Conference  (Live)
09/13/16 at 10:00 a.m. ET
Coherus Biosciences at Morgan Stanley Global Healthcare Conference
Tuesday, September 13, 2016 10:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Overview

Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Recent News

DateTitle
08/31/16Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective August 31, 2016, the compensation committee of the company’s board of directors granted 6 new employees options to purchase an aggregate of 80,000 shares of the company’s common stock with a per share exercise price of $29.77, the closing trading price on the grant date.  The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commence... 
08/09/16Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results
Continued execution on multiple fronts positions the company strongly for the second-half of 2016 and beyond REDWOOD CITY, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reported financial results and reviewed corporate events for the second quarter ended June 30, 2016. Corporate Highlights for the Second Quarter 2016 Include: Immunology (anti-TNF) therapeutic franchise: CHS-1420 (adalimumab (HUMIRA®) biosimilar) Received f... 
08/09/16Coherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
REDWOOD CITY, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced submission of the biologics license application (BLA) for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate, to U.S. FDA under the 351(k) pathway.   The BLA submission is supported by similarity data from analytical, pharmacokinetic, pharmacodynamic and immunogenicity studies comparing CHS-1701 and Neulasta.    “The CHS-1701 BLA submission marks a significant milestone ... 
08/08/16Coherus BioSciences Announces Positive Topline Phase Three Results for CHS-1420 (Humira® Biosimilar Candidate) in Patients with Psoriasis
REDWOOD CITY, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reported topline results from an ongoing Phase 3 clinical study of CHS-1420, an adalimumab (Humira®) biosimilar candidate. This study met its primary endpoint demonstrating similarity between CHS-1420 and Humira with respect to percentage of subjects achieving 75% improvement in psoriasis area and severity index (PASI-75) at Week 12.  The 95% confidence intervals for the difference betwe... 
View All

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Coherus Biosciences Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

CHRS (Common Stock)

ExchangeNASDAQ (US Dollar)
Price$29.77
Change (%) Stock is Up 0.26 (0.88%)
Volume292,243
Data as of 08/31/16 4:00 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet